New insider activity at Chemed ( (CHE) ) has taken place on May 8, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Patrick Grace has trimmed his stake in Chemed, selling 60 shares of the company’s stock in a transaction valued at $25,546. This insider move provides a glimpse into recent activity within Chemed’s leadership ranks, as investors often watch such sales closely for potential signals about executive sentiment toward the company’s future performance.
Recent Updates on CHE stock
Chemed shares surged over 10% as a strong Q1 beat and a rare post-Q1 guidance increase prompted RBC Capital to lift its valuation outlook, driven mainly by VITAS’ robust census growth and margin outperformance that pushed EBITDA and EPS well above forecasts. Analysts highlighted that faster-than-expected recovery from prior Medicare Cap issues, higher hospice admissions and improved ADC guidance, along with share repurchases, outweighed ongoing Roto-Rooter margin pressure from elevated marketing spend and weather-related disruptions.
Spark’s Take on CHE Stock
According to Spark, TipRanks’ AI Analyst, CHE is a Outperform.
Score driven primarily by strong financial performance (profitability, accelerating revenue, and robust free cash flow). The earnings call was supportive due to raised FY2026 guidance led by VITAS, partially offset by Roto-Rooter margin headwinds. Technical signals are mixed (negative MACD and below the 200-day), and valuation is reasonable but held back by a low dividend yield.
To see Spark’s full report on CHE stock, click here.
More about Chemed
YTD Price Performance: -0.35%
Average Trading Volume: 266,824
Technical Sentiment Signal: Sell
Current Market Cap: $5.65B